Based on the Neximmune Inc stock forecast from 0 analysts, the average analyst target price for Neximmune Inc is not available over the next 12 months. Neximmune Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Neximmune Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Neximmune Inc’s stock price was USD 0.00. Neximmune Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -100.00% over the last year.
No recent analyst target price found for Neximmune Inc
No recent average analyst rating found for Neximmune Inc
Company Overview Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Read Less
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its propri...Read More
Frequently Asked Questions About Neximmune Inc (NEXI) Stock
Stock Target Advisor's fundamental analysis for Neximmune Inc's stock is Bearish.
Unfortunately we do not have enough data on NEXI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NEXI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on NEXI's stock to indicate if its overvalued.
The last closing price of NEXI's stock was USD 0.00.
The most recent market capitalization for NEXI is USD 139.00.
Unfortunately we do not have enough analyst data on NEXI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Neximmune Inc's stock.
As per our most recent records Neximmune Inc has 6 Employees.
Neximmune Inc's registered address is 9119 Gaither Road, Gaithersburg, MD, United States, 20877.
You can get more information about it from Neximmune Inc's website at https://www.neximmune.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Neximmune Inc (NEXI) Stock
Stock Target Advisor's fundamental analysis for Neximmune Inc's stock is Bearish.
Unfortunately we do not have enough data on NEXI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on NEXI's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on NEXI's stock to indicate if its overvalued.
The last closing price of NEXI's stock was USD 0.00.
The most recent market capitalization for NEXI is USD 139.00.
Unfortunately we do not have enough analyst data on NEXI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Neximmune Inc's stock.
As per our most recent records Neximmune Inc has 6 Employees.
Neximmune Inc's registered address is 9119 Gaither Road, Gaithersburg, MD, United States, 20877.
You can get more information about it from Neximmune Inc's website at https://www.neximmune.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NEXI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
